

For Immediate Release

MEDX HEALTH ANNOUNCES CHANGE IN FINANCING

Funding to Support US and International Distributor Agreements Remains Priority

Mississauga, Ontario - July 16, 2008 – MedX Health Corp. (TSXV: MDX) ("MedX" or the "Company") today announced that it has discontinued its financing relationship with Research Capital, the firm that had begun their second round of financing in May 2008. The low level laser therapy device manufacturer continues to seek funding to help achieve the original goal of expanding its commercialization plans.

“We plan to efficiently close out this next round of financing as we continue to grow our product line and business opportunities.” said Steve Guillen, president & chief executive officer. “The recently announced distribution partnerships with Technology4Medicine, along with our recent expansion internationally via a new network of worldwide distributors, are evidence of our commitment to become a global leader in low level laser therapy,” said Mr. Guillen.

About MedX Health Corp.

MedX is a leading North American developer and manufacturer of low level laser medical devices, including dental, rehabilitation and wound care products. MedX is the world’s only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for and bringing the non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments.

MedX’s strategy is to build upon its success in bringing relief of symptoms in a non-pharmacologic manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as well as developing and commercializing advanced products in the dental and wound-care markets that will position the company to increase revenue. In addition, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its “*Photobandage*”, a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development of marketing and sales.

For further information, please contact:

Steve Guillen
President & Chief Executive Officer
MedX Health Corp.
Phone: (905) 826-0766
Email: guillen@medxhealth.com

Nelson Smith
Taddle Creek Capital
Phone: (416) 565-7518
Email: smith@medxhealth.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.